Assessment of mesalamine in the alterations of metabolic parameters in comorbid ulcerative colitis and metabolic syndrome patients: A retrospective study

Autor: Snow He, Arroyo-Mercado Fm, Rakov Ne, Eliseo F. Castillo, Graziella Rangel Paniz, Choi Ee, Christina Ling

BACKGROUND & AIMSIt is unclear how the gut targeting medication mesalamine alters metabolic parameters associated with Metabolic Syndrome (MetS). We completed a retrospective analysis on ulcerative colitis (UC) and MetS comorbid patients receiving me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e082b3156e2b33a16f6ffa121141a21
https://doi.org/10.1101/2021.05.27.21257690

Individuals with Metabolic Syndrome Show Altered Fecal Lipidomic Profiles with No Signs of Intestinal Inflammation or Increased Intestinal Permeability.

Autor: Coleman MJ; University of New Mexico School of Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Espino LM; University of New Mexico School of Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Lebensohn H; University of New Mexico School of Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Zimkute MV; Clinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Yaghooti N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Ling CL; Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Gross JM; Clinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Listwan N; Clinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Cano S; Clinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Garcia V; Clinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Lovato DM; Clinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Tigert SL; Clinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Jones DR; Metabolomics Core Resource Laboratory, New York University Langone Health, New York, NY 10016, USA., Gullapalli RR; Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Rakov NE; Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Torrazza Perez EG; Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA., Castillo EF; Clinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.; Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.

Publikováno v: Metabolites [Metabolites] 2022 May 11; Vol. 12 (5). Date of Electronic Publication: 2022 May 11.